NCT04354870View on ClinicalTrials.gov

COVID-19 PrEP HCW HCQ Study

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

September 15, 2020

Study Completion Date

October 1, 2020

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine (HCQ)

Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04354870 - COVID-19 PrEP HCW HCQ Study | Biotech Hunter | Biotech Hunter